Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4406

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-4406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for fluticasone propionate and salmeterol inhalation powder 100 mcg / 50 mcg, containing 60 blisters. The label specifies storage instructions, repackaging by RemedyRepack Inc., and includes warnings and dosage directions. Manufacturer is Hikma, Berkeley Heights, NJ.*

FDA Label Image

Figurec.jpg (Figurec)

Illustration showing a person holding a respiratory powder inhaler with both hands. One hand grasps the inhaler while the other is positioned to rotate or slide the mouthpiece in the direction indicated by a right-pointing arrow below, likely demonstrating the step to prepare the inhaler for use.*

FDA Label Image

Figuref.jpg (Figuref)

An instructional illustration showing two hands holding a respiratory powder inhaler. The image emphasizes twisting the blue base of the inhaler in the direction indicated by a curved arrow. The inhaler displays a dose counter reading "59." This diagram guides proper device activation for fluticasone propionate and salmeterol powder inhalation.*

FDA Label Image

Figureh.jpg (Figureh)

An instructional illustration showing a close-up view of a respiratory inhaler device with a numbered dose counter display. The number '5' is highlighted on the digital dose counter, indicating remaining doses.*

FDA Label Image

Fluticasone-propionate-chemical.jpg (Fluticasone Propionate Chemical)

Chemical structure diagram of the active ingredient fluticasone propionate, showing its molecular framework and functional groups.*

FDA Label Image

Figure-5-08172021.jpg (Image 03)

A line graph depicting percentage change in FEV1 (forced expiratory volume in 1 second) over time for three groups: Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg, Fluticasone Propionate 250 mcg, and Placebo. The x-axis spans from Day 1 to Week 24 and endpoint, while the y-axis shows percentage change up to 30%. The Fluticasone Propionate and Salmeterol group shows the highest sustained improvement, followed by Fluticasone alone and Placebo.*

FDA Label Image

Figure-4.jpg (Image 04)

A line graph depicting the percentage change in FEV1 over 24 weeks plus an endpoint for three groups: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, salmeterol 50 mcg, and placebo. The x-axis shows weeks, while the y-axis represents the percentage change in FEV1. Each group is represented by distinct markers with corresponding sample sizes noted below the graph.*

FDA Label Image

Figure-1a (Image 05)

A line graph showing percent change in FEV1 over 12 weeks comparing four treatments: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The combination treatment shows the greatest increase in FEV1, followed by fluticasone propionate, salmeterol, and placebo. Sample sizes for each group at various weeks are listed below the graph.*

FDA Label Image

Figure-2.jpg (Image 06)

A line graph titled 'First Treatment Day' showing the percentage change in FEV1 over 12 hours from baseline at Day 1. The graph compares four groups: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily (triangle), salmeterol 50 mcg twice daily (circle), fluticasone propionate 100 mcg twice daily (square), and placebo (diamond). The percentage change generally rises quickly then declines over time, with combination therapy showing the highest increase.*

FDA Label Image

Figure-3a (Image 07)

A line graph showing the percent change in FEV1 relative to Day 1 baseline over a 12-hour period on the last treatment day (Week 12). Four treatment groups are compared: Fluticasone Propionate and Salmeterol Inhalation Powder 100 mcg/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone Propionate 100 mcg twice daily, and Placebo. Data points indicate mean changes with time on the x-axis (hours) and percent change on the y-axis from 0 to 45%.*

FDA Label Image

Image1.jpg (Image1)

Illustration of a fluticasone propionate and salmeterol inhalation powder device. The diagram labels key parts including the outer case, mouthpiece, lever, counter, and thumb grip. The top label shows the product name, strength (100 mcg/50 mcg), and blister count (60). This image details device components for respiratory drug administration.*

FDA Label Image

Salmeterol-xinafoate-chemical.jpg (Salmeterol Xinafoate Chemical)

Chemical structure diagram showing the molecular composition of fluticasone propionate and salmeterol, active ingredients in the respiratory powder inhalation product by Remedyrepack Inc.*

FDA Label Image

Ww-image-2.jpg (Ww Image 2)

Instructional diagram showing hands holding a respiratory inhaler device with a dose counter displaying '60'. An arrow indicates a rotational action, likely demonstrating how to prepare or activate the inhaler before use.*

FDA Label Image

Ww-image-4.jpg (Ww Image 4)

An illustration depicting a person using a respiratory inhalation device by REMEDYREPACK INC. The individual is holding the inhaler near their mouth, demonstrating the typical inhalation technique for a powder dosage form of fluticasone propionate and salmeterol.*

FDA Label Image

Ww-image-5.jpg (Ww Image 5)

Illustration showing a person using a respiratory inhalation device to administer powdered medication, likely representing the use of fluticasone propionate and salmeterol powder inhalation.*

FDA Label Image

Ww-image-7.jpg (Ww Image 7)

An illustration of a person leaning over a sink and spitting out liquid. A glass with some water is placed nearby on the counter. The image likely depicts an oral rinse or spitting action.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.